UTI symptoms can be alleviated with home remedies such as staying hydrated, drinking unsweetened cranberry juice, using heat ...

Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participants, representing 82% of target enrollment. Enrollment completion ...

CU-06 is under clinical development by Curacle and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 82% phase transition success rate ...

While many treatments are approved by the Food and Drug Administration (FDA) for both forms of IBD, others are only approved for either Crohn's disease or ulcerative colitis. What's more, certain ...

Introduction Long standing ulcerative colitis (UC) is associated with an increased risk of colorectal cancer (CRC), with a cumulative incidence of about 15% at 30 years. The finding of a colonic ...

One treatment for ulcerative colitis, which is surgery to remove the colon (a colectomy ... Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based cohorts: ...

Cleveland Clinic digestive health experts come to the rescue with "maneuvers and techniques," as they say, to get things ...

GS-1427 is under development for the treatment of ulcerative colitis. The drug candidate acts by targeting integrin alpha4 and beta7 receptors. It is administered through oral route. It was also under ...

Ulcerative colitis causes ulcers in your large intestine that can lead to gastrointestinal problems. Some people with ulcerative colitis develop symptoms in other body parts, such as their joints ...

For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months compared with tofacitinib, according to a study published in the December ...

diff) is a bacterial infection that commonly affects people with ulcerative colitis (UC ... so you may need to change or intensify your treatment plan. People with UC and C.